Aptose Biosciences

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the Piper Sandler 33rd Annual Healthcare Conference, being held virtually.

Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference

Aptose Biosciences Inc.'s (APTO) CEO William Rice on Q3 2021 Results - Earnings Call Transcript

- Conference call and webcast at 5:00 pm ET today -

Aptose Reports Results for the Third Quarter 2021

HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation

Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting

HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients

Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239

SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30, 2021, and provide a corporate update on Thursday, November 11, 2021, after the close of the market.

Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021

Janet Clennett, CPA, appointed Vice President, Finance

Aptose Expands Senior Leadership Team

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the upcoming conferences in September 2021:

Aptose to Present at September Investor Conferences

Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptose Biosciences (APTO) Moves to Buy: Rationale Behind the Upgrade

Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aptose's second quarter update was undramatic, with management indicating that they've fully enrolled their Phase I luxeptinib studies at 750mg and are moving on to 900mg. Dose escalation awaits in the APTO-253 AML/MDS study, but management is also going to start enrolling patients with certain eligible B-cell cancers.

Aptose: High Risk, High Reward. Watch Its Phase I Studies

Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2021 Results - Earnings Call Transcript

- Conference call and webcast at 5:00 pm EDT today -

Aptose Reports Results for the Second Quarter 2021

SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide a corporate update on Tuesday, August 3, 2021, after the close of the market.

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or refractory B cell malignancies. In Relapsed or Refractory AML or High-Risk MDS trial, APTO-253 has been well-tolerated in the patients treated at 20, 40, 66, 100, and 150 mg/m2 over multiple cycles supporting continued dose escalation.

Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress

SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update event being held today, Friday, June 11, 2021, at 8:00 a.m. ET, in concurrence with participation at the EHA2021 Virtual Congress (EHA). The event is focused on the current clinical status of luxeptinib, Aptose's oral, first-in-class FLT3 and BTK kinase inhibitor currently in two Phase 1 a/b trials, one trial in patients with relapsed or refractory acute myeloid leukemia (AML), and the other trial in patients with relapsed or refractory B cell malignancies. The live and archived webcast of the presentation is available on Aptose's website here.

Aptose Presents Highlights from EHA During Corporate Update Event

APTO is presenting new data at EHA21 for its Btk inhibitor, Luxeptinib.

Aptose: Cancer Trial Catalyst Ahead At EHA21

Fortress Biotech

Mustang Bio

Regulus Therapeutics

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks To Watch For June 2021

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS

Aptose to Hold Corporate Update Friday, June 11th

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Aptose (APTO) Stock?

SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences:

Aptose to Present at Upcoming Investor Conferences

Aptose Biosciences Inc. (APTO) CEO William Rice on Q1 2021 Results - Earnings Call Transcript

- Conference call and webcast at 4:30 pm EDT today -

Aptose Reports Results for the First Quarter 2021

SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2021, and provide a corporate update on Tuesday, May 4, 2021, after the close of the market.

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021

Cronos Group

Kinross Gold

Costamare

CarLotz

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

News for Aptose Biosciences Stock (APTO)